IL6 and neoplasm: In order to avoid immune surveillance, tumor cells employ a variety of strategies, including downregulating tumor antigens or impairing antigen-presenting cells, secreting pro-tumoral cytokines (tumor growth factor (TGF-β), IL-6, vascular endothelial growth factor (VEGF)), losing adhesion molecules and elevated galectin levels, generating epithelial mesenchymal transition, and overexpressing inhibitory immune checkpoints [9].